Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2008-01-29
2008-01-29
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S208100
Reexamination Certificate
active
07323174
ABSTRACT:
The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived from T cell receptors, or a derivative thereof. The present invention also relates to peptides derived from T-cell receptors, and derivatives thereof, which are useful in such methods.
REFERENCES:
patent: 5911990 (1999-06-01), Marchalonis et al.
patent: 5962319 (1999-10-01), Ogawa et al.
patent: 6150337 (2000-11-01), Tam
patent: 2004/0248192 (2004-12-01), Marchalonis et al.
patent: 0 109 942 (1984-05-01), None
patent: 0 180 564 (1986-05-01), None
patent: 0 231 039 (1987-08-01), None
patent: 2 189 141 (1987-10-01), None
patent: WO 91/10736 (1991-07-01), None
patent: WO 92/01715 (1992-02-01), None
patent: WO 94/18317 (1994-08-01), None
patent: WO 95/18145 (1995-07-01), None
patent: WO 96/21028 (1996-07-01), None
patent: WO 97/35991 (1997-10-01), None
patent: WO 02/094860 (2002-11-01), None
Davis, M. M. and Y.-H. Chien, 1999, “T-cell antigen receptors”, in Fundamental Immunology, Fourth Edition, W. E. Paul, ed., Lippincott-Raven Publishers, Philadelphia, pp. 341-344, 346, and 347.
Graziosi, C., et al., 1994, “Lack of evidence for dichotomy of TH1 and TH2 predominance in HIV-infected individuals”, Science 265:248-252.
Maggi, E., et al., 1994, “Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells”, Science 265:244-248.
Romagnani, S., et al., 1994, “An alternative view of the Th1/Th2 switch hypothesis in HIV infection”, AIDS Res. Human Retrovir. 10(5):III-IX.
Shearer, G. M. and M. Clerici, 1992, “T helper cell immune dysfunction in asympotomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation”, Chem. Immunol. 54:21-43.
Yarchoan, R. and S. Broder, 1992, “Correlations between the in vitro and in vivo activity of anto-HIV agents: implications for future drug development”, J. Enzyme Inhibit. 6:99-111.
Gait, M. J. and K. Karn, 1995, “Progress in anti-HIV structure based design”, TIBTECH 13:430-438.
Öberg, B. and. L. Vrang, 1990, “Screening for new agents”, Eur. J. Clin Microbiol. Infect. Dis. 9(7):466-471.
Evavold, B. D., et al., 1993, “Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands”, Immunol. Today 14(12):602-9 (abstract provided).
Mandrenas, J. and R. N. Germain, 1996, “Variant TCR ligands: new insights into the molecular basis of antigen-dependent signal transduction and T-cell activation”, Sem. Immunol. 8(2):83-101 (abstract provided).
Liang, B., et al., 1998, Injection of T-cell receptor peptide reduces immunosenescence in aged C57BL/6 mice, Immunol. 93:462-468.
Liang, B., et al., 1996, T-cell receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function, Immunol. 87:198-204.
Liang, B., et al., 1996, Effects of vaccination against different T cell receptors on maintenance of immune function during murine retrovirus infection, Cell. Immunol. 172:126-134.
Watson, R. R., et al., T cell receptor VB complementarity-determining region 1 peptide administration moderates immune dysfunction and cytokine dysregulation induced by murine retrovirus infection, J. Immunol. 155:2282-2291.
Watson, R. R., et al., T cell receptor VB complementarity-determining region 1 peptide administration moderates immune dysfunction and cytokine dysregulation induced by murine retrovirus infection, 1995 J. Immunol. 155:2282-2291.
Marchalonis et al., 2001,T-Cell Receptor-Derived Peptides in Immunoregulation and Therapy of Retrovirally Induced Immunosuppression, Critical Reviews in Immunology 21:57-74.
Sepulveda et al., 2003,T-Cell Receptor Vβ8.1 Peptide Reduces Coxsackievirus-induced Cardiopathology during Murine Acquired Immunodeficiency Syndrome, J. Cardiovasc. Pharmacol. 41:489-497.
Lake et al., 1994,Autoantibodies to the α/β T-cell receptors in human immunodeficiency virus infection: Dysregulation and mimicry, Proc. Natl. Acad. Sci. USA 91:10849-10853.
Marchalonis et al., 1994.Synthetic Autoantigens of Immunoglobulins and T-Cell Receptors: Their Recognition in Aging, Infection, and Autoimmunity, Proceedings of the Society for Experimental Biology and Medicine pp. 129-147, Academic Press, NY.
Marchalonis et al., 1997,Analysis of Autoantibodies to T-Cell Receptors Among HIV-infected Individuals: Epitope Analysis and Time Course, Clinical Immunology and Immunopathy 82(2):174-189.
Akuffo et al., 1999, “Natural killer cells in cross-regulation of IL-12 by IL-10 in Leishmania antigen-stimulated blood donor cells,” Clin. Exp. Immunol. 117(3):529-34.
Albright et al., 2000, “Soluble receptors and other substances that regulate Proinflammatory cytokines in young and aging humans,” J. Gerontol. A Biol. Sci. Med. Sci. 55(1):B20-5.
Aleman et al., 2000, “Interleukin-12 amplifies the M. leprae hsp65-cytotoxic response in the presence of tumour necrosis factor-alpha and interferon-gamma generating CD56+ effector cells: interleukin-4 downregulates this effect,” Scand. J. Immunol. 51(3):262-70.
Boon, 1993, “Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy,” Int. J. Cancer 54(2):177-80.
Bourdette et al., 1994, “Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides,” J. Immunol. 152(5):2510-9.
Bradley et al., 1994, “Alteration of in vivo cytokine gene expression in mice infected with a molecular clone of the defective MAIDS virus,” J. Acquir. Immune Defic. Syndr. 7(1):1-9.
Castle et al., 1997, “Evidence of enhanced type 2 immune response and impaired upregulation of a type 1 response in frail elderly nursing home residents,”Mech. Ageing Dev. 94(1-3):7-16.
Cherwinski et al., 1987, “Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies,” J. Exp. Med. 166(5):1229-44.
Clerici et al., 1993, “A TH1→TH2 switch is a critical step in the etiology of HIV infection,” Immunol. Today 14(3):107-11.
De Carli et al., 1994, “Human Th1 and Th2 cells: functional properties, regulation of development and role in autoimmunity,” Autoimmunity 18(4):301-8.
Dehghanpisheh et al., 1995, “Production of IgG autoantibodies to TCRs in mice infected with the retrovirus LP-BM5.” Int. Immunol. 7(1):31-6.
Dehghanpishah et al., 1997, “Retrovirally induced mouse anti-TCR monoclonals can synergize the in vitro proliferative T cell response to bacterial superantigens,” Scan.J. Immunol. 45(6):645-54.
Fauci et al., 1993, “Multifactorial nature of human immunodeficiency virus disease: implications for therapy,” Science 262(5136):1011-8.
Fernandez-Gutierrez et al., 1999, “Early lymphocyte activation in elderly humans: impaired T and T-dependent B cell responses,” Exp. Gerontol. 34(2):217-29.
Garcia et al., 1999, “IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection,” J. Immunol. 162(10):6114-21.
Gazzinelli et al., “CD4+ subset regulation in viral infection. Preferential activation of the Th2 cells during progression of retrovirus-induced immunodeficiency in mice,” J. Immunol. 148(1):182-8.
Graziosi et al., 1996, “Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection,” Proc. Natl. Acad. Sci. U.S.A. 93(9):4386-91.
Haynes et al., 1996, “Toward an understanding of the correlates of protective immunity to HIV infection,&#x
Marchalonis John J.
Schluter Samuel F.
Watson Ronald R.
Arizona Board of Regents on Behalf of the University of Arizona
Jones Day
Parkin Jeffrey S.
LandOfFree
Modulation of immune response and methods based thereon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immune response and methods based thereon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immune response and methods based thereon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2814385